GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro have fundamentally changed the management of obesity and type 2 diabetes. These medications deliver meaningful weight loss and improved glycemic control for patients. However, their clinical effectiveness comes with dramatic cost escalation that is rapidly reshaping employer-sponsored benefits plans.
Employers face a critical decision: whether to cover these medications at all for weight loss. Currently, only about 25% of employers cover weight loss drugs in their pharmacy benefits plans, leaving many grappling with this initial choice. For those who decide to provide coverage, the next challenge is managing the significant costs associated with these therapies. With nearly 42% of Americans classified as obese and a large portion of employees potentially eligible for GLP-1s to manage their condition, the financial implications are substantial.
Recent research underscores this exponential growth. Between 2018 and 2023, national spending on GLP-1 medications increased by more than 500%. Spending soared from $13.7 billion to $71.7 billion. Ozempic alone grew from $410 million in annual spend to more than $26 billion.
Employers must strike a careful balance. They need to make these therapies accessible to the employees who benefit, while also protecting the long-term sustainability of their pharmacy benefits plans.
The rapid rise and financial strain of GLP-1s
GLP-1 drugs initially targeted type 2 diabetes but quickly became standard for chronic weight management. Evidence of substantial weight loss and comorbidity reduction drove unprecedented member demand. For employers, the consequence is a massive surge in pharmacy plan spending.
Traditional injectable GLP-1 therapies cost between $1,000 and $1,500 per patient per month. Because patients typically require these medications long-term to maintain results, they quickly consume a large share of overall plan costs. Left unchecked, this trend forces tough choices regarding premiums, out-of-pocket costs, and coverage limits.
The shifting landscape: oral options and DTC access
Recent market developments introduce new variables into the GLP-1 equation. Lower-cost pill forms and direct-to-consumer (DTC) access are altering how members acquire these medications. These changes bring both opportunities and complexities for employer plans.
Pill forms of GLP-1s offer lower-cost alternatives to traditional injections. Launched in early 2026, the Wegovy pill from Novo Nordisk is the first GLP-1 pill specifically approved for weight management. Eli Lilly’s Foundayo offers a once-daily pill alternative to the weekly Zepbound shot, while Rybelsus manages blood sugar in type 2 diabetes.
These oral options shift the pricing paradigm. Self-pay costs for the Wegovy pill generally range from $149 to $299 per month. For insured individuals, out-of-pocket costs can drop to just $25 per month. While this lower price point could reduce the per-member cost burden on employer plans, the increased accessibility and convenience of a daily pill will likely drive higher overall utilization.
Simultaneously, direct-to-consumer (DTC) GLP-1 programs are changing how members access care. Manufacturer platforms like LillyDirect and NovoCare bypass traditional insurance pathways, offering convenient access to weigh-loss medications for monthly self-pay costs typically ranging from $349 to $449.
While these platforms provide options for employees whose plans do not cover weight loss drugs, they bypass employer-sponsored prior authorization (PA) requirements and independent clinical oversight. Patients may receive prescriptions without comprehensive medical evaluations or the lifestyle support necessary for long-term success. Furthermore, some platforms offer compounded versions of these drugs that are not subject to standard regulatory approval and oversight, introducing potential safety risks.
Three pillars for sustainable management
Addressing the GLP-1 dilemma demands a structured, proactive approach. Implementing these three core strategies can help strike the right balance between care and cost control:
1. Smart plan design
Begin with a well-defined plan design that addresses both injectables and new oral options:
- Targeted coverage: Restrict coverage to approved clinical indications. Ensure members use drugs like Ozempic for Type 2 diabetes and Wegovy for clinical obesity.
- Tiered copays and exclusions: Place GLP-1s on higher cost-sharing tiers to encourage evaluation of cost-effective alternatives first, including the new oral medications.
- Flexibility: Collaborate with a pharmacy benefits optimizer to determine when and for whom GLP-1 coverage is medically appropriate.
2. Robust utilization management
Next, ensure GLP-1 usage aligns with evidence-based clinical criteria to eliminate wasteful spending:
- Strict prior authorization: Require documented diagnosis and relevant comorbidities that meet U.S. Food and Drug Administration (FDA) guidelines before approving GLP-1 therapy.
- Ongoing reauthorization: Base continued coverage on patients meeting weight reduction or health improvement milestones.
- Enforce step therapy: Require a trial of generic weight-loss medications or structured lifestyle programs before authorizing expensive GLP-1 drugs.
Independent clinical management delivers substantial results. By strictly managing utilization, plans routinely see high percentages of participants achieve meaningful reductions in body weight while safely discontinuing unnecessary metabolic medications.
3. Integrate lifestyle and clinical solutions
Medication alone is not a comprehensive, long-term solution for weight-related chronic diseases. Patients require holistic support to achieve lasting health improvements:
- Comprehensive programs: Pair GLP-1 use with nutrition, behavioral therapy, and exercise coaching.
- Plan stewardship: Require active participation in clinical lifestyle programs before approving GLP-1 therapy to protect members from the risks of unmonitored DTC access.
Solutions that integrate personal coaching, independent clinical oversight, and sustainable lifestyle changes can drive meaningful weight loss. For example, RxBenefits, in partnership with Tria Health, offers the Choose to Lose program, which helps deliver significant savings by reducing unnecessary medication use over time.
The GLP-1 trend will intensify as new therapies reach the market, oral options expand, and coverage indications evolve. Employers must remain vigilant and adapt their benefits strategies to account for both rising utilization and alternative access channels.
By embracing evidence-based plan management, robust clinical oversight, and integrated health solutions, employers can safeguard both plan viability and employee well-being in the complex era of GLP-1 medications.
Learn more:
The Four Forces That Shape – and Reshape – Healthcare in 2026, Feb. 2, 2026
Four Strategies for Managing GLP-1 Cost Trends, Nov. 10, 2025
GLP-1s: The Billion-Dollar Buzz That Keeps Growing, Oct. 31, 2025
